[1] |
Britt NS,Ritchie DJ,Kollef MH,et al.Clinical epidemiology of carbapenem resistant gram-negative sepsis among hospitalized patients:shifting burden of disease[J].Am J Infect Control,2018,4(18):30 180-30 189.
|
[2] |
陈佰义,何礼贤,胡必杰.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85
|
[3] |
卫生部.医院感染诊断标准:试行[S].2001-01-02.
|
[4] |
尚红,王毓三,申子瑜.全国临床检验操作规范[M].3版.北京:人民卫生出版社,2014:720-721.
|
[5] |
Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing:twenty-fifth informational supplement:M100-S25[S].2015-01-30.
|
[6] |
陈静.鲍曼不动杆菌感染分布特征及耐药性变迁分析[J].浙江临床医学,2017,18(2):357-358
|
[7] |
胡付品,郭燕,朱德妹,等.2016年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2017,17(7):481-491
|
[8] |
肖凌.ICU鲍曼不动杆菌定植的多因素分析及临床意义探讨[J].临床肺科杂志,2017,22(4):666-669
|
[9] |
马明远,徐杰,于娜,等.综合ICU内鲍曼不动杆菌感染的耐药性和相关因素分析[J].中华危重病急救医学,2013,25(11):686-689
|
[10] |
Munoz-Price LS,Arheart K,Nordmann P,et al.Eighteen years of experience with Acinetobacter baumannii in a tertiary care hospital[J].Critical Care Medicine,2013,42(12):2733-2742
|
[11] |
王国恩,马琪,刘敏龙,等.ICU病房鲍曼不动杆菌感染状况及耐药性分析[J].中国医药导报,2015,12(27):153-155
|
[12] |
袁红萍,张霞军,周文俊.鲍曼不动杆菌院内感染及相关危险因素分析[J].中国药业,2017,26(22):15-18
|
[13] |
李兴国,温汉春等.ICU患者鲍曼不动杆菌院内感染的危险因素和住院费用分析[J].广西医学,2018,40(8):924-927
|
[14] |
Janahiraman S,Aziz MN,Hoo FK,et al.Resistance paterns of multidrug resistant Acinetobacter baumannii in an ICU of teriary care hospital,malaysia[J].Pak J Med Sci,2015,31(6):1383-1388
|
[15] |
刘秋萍,徐凌.耐药鲍曼不动杆菌药物治疗的研究进展[J].实用药物与临床,2018,21(2):212-217
|
[16] |
Djordjevic ZM,Folic MM,Folic ND,et al.Risk factors for hospital infection caused by carbapenem-resistant Acinetobacter baumannii[J].Infect Dev Ctries,2016,10(10):107
|
[18] |
赵忺,刘长庭.鲍曼不动杆菌的耐药机制研究进展[J].解放军医学院学报,2017,38(5):490-493
|
[19] |
李璇,旷南岳,漆新文.抗菌药物对鲍曼不动杆菌多重耐药及感染预后的影响[J].医药导报,2018,37(3):325-328.
|
[17] |
Thwaites CL,Lundeg G,Dondorp AM.Recommendations for infection management in patients with sepsis and septic shock in resource-limited settings[J].Intensive Care Med.2016,42(12):2117-2118
|